




RealRate

PHARMACEUTICAL 2016

Arena Pharmaceuticals INC
Rank 115 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Arena Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arena Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Arena Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 317%, being 54% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	174,838
Cost of Goods Sold	0
Intangible Assets	7,775
Liabilities, Current	49,896
Liabilities, Non-Current	0
Other Assets	2,351
Other Compr. Net Income	-4,087
Other Expenses	17,147
Other Liabilities	0
Other Net Income	-4,781
Other Revenues	38,326
Property and Equipment	71,828
Research and Development	88,411
Selling, General and Administrative Expense	35,966

Output Variable	Value in 1000 USD
Assets	256,792
Liabilities	49,896
Expenses	141,524
Revenues	38,326
Stockholders Equity	206,896
Net Income	-107,979
Comprehensive Net Income	-110,022
BaseVar	247,703
ECR before LimitedLiability	222%
Economic Capital Ratio	317%